Skip to main content
letter
. 2022 Oct 25;46:39–42. doi: 10.1016/j.euros.2022.10.002

Table 1.

Estimated 5 - yr MFS (according to the Leibovich score [6]) and 5 - yr DFS (according to the ASSURE model [7] ) for all patients eligible for adjuvant immunotherapy according to the KEYNOTE - 564 study criteria [1], stratified by pT stage, pN stage , and W orld Health Organization /International Society of Urological Pathology grade.

graphic file with name fx1.gif

aPembro = adjuvant pembrolizumab; ccRCC = clear - cell renal cell carcinoma; DFS = disease - free survival; HiR = high risk; IR = intermediate risk; KN - 564 KEYNOTE - 564 study; LR = low risk; LS = Leibovich score; MFS = metastasis - free survival VI = va scular invasion .

a Using the online calculator at https://cancernomograms.com/nomograms/492.